Combined with weight loss, improved body image, and normalized cycles, many women with PCOS report improved sexual satisfaction on semaglutide, even when the general population shows mixed results
Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data
Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications
The column temperature was maintained at 55 C, while the autosampler tray was set at 4 C
Kinoshita M, Ogawa Y, Hama N, Ujiie I, Hasegawa A, Nakajima S, et al